期刊文献+

微型营养评价量表在老年阿尔茨海默病患者中的应用 被引量:2

The application of MNA in elderly patients with alzheimer's disease
下载PDF
导出
摘要 目的 观察老年阿尔茨海默病(Alzheimer's disease,AD)患者营养状况及血叶酸、VitB12水平,并分析认知功能对老年患者营养状况影响.方法共纳入AD患者101例.以微型营养评价量表(MNA)和痴呆评定量表(CDR)为工具检查所有研究对象的营养状态和认知功能,分为轻度AD组(51例,CDR 1分)和中重度AD组(50例,CDR 2 ~3分),根据患者量表得分及生化检测指标进行数据分析.结果与轻度AD组相比,中重度AD组患者MNA总得分(23.74±4.46) vs (26.86±3.13)、整体评估得分(6.32±0.67)vs(7.46±0.44)、膳食评估得分(6.68 ±0.17)vs (7.58±0.38)等降低(P<0.05),BMI降低[(21.33±4.08) kg/m2 vs (24.67±4.36) kg/m2,P<0.01].多元回归逐步方程:MNA评分=30.860-0.215年龄-0.049CDR评分+0.269血叶酸水平.结论MNA得分随CDR得分升高而降低.年龄、CDR评分与MNA评分呈负相关,血叶酸水平与MNA评分呈正相关. Objective To investigate the nutritional status (including folic acid and VitaminB12) in patients with Alzheimer's disease (AD) and the impact of cognitive function on nutritional status.Methods A total of 101 AD patients were divided into mild AD group (n=51) and moderate to severe AD group (n =50).The mini-nutritional assessment (MNA) and clinical dementia rating (CDR) were used to determine nutritional status and cognitive function.Biochemical indicator was measured.SPSS13.0 was used to perform statistic analysis.Results MNA total score in the moderate to severe AD group was (23.74±4.46),and (26.86±3.13) in the mild AD group.Overall evaluation score was (6.32 ±0.67) in the moderate to severe AD group,and (7.46±0.44) in the mild AD group.The dietary assessment score was (6.68±0.17) in the moderate to severe AD group,and 7.58±0.38 in the mild AD group (P all < 0.05).The BMI score was (21.33 ±4.08) kg/m2 in the moderate to severe AD group and (24.67±4.36) kg/m2 in the mild AD group (P<0.01).The MNA scores=30.860-0.215age-0.049CDR scores+0.269 folic degree.Conclusions MNA Score decreased with the increase of CDR score.Age and CDR score were negatively correlated with the MNA scores.Folic degree was positively correlated with the MoCA scores.
出处 《老年医学与保健》 CAS 2014年第5期333-336,共4页 Geriatrics & Health Care
关键词 阿尔茨海默病 营养 微型营养评价量表 临床痴呆评定量表 叶酸 维生素B12 Alzheimer's disease Nutrition MNA CDR Folic acid VitaminB12
  • 相关文献

参考文献3

二级参考文献38

  • 1Cutler A J, Kalali AH, Weiden PJ, et al. Four-week, doubleblind, placebo- and ziprasidone-controlled trial of itoperidone in patients with acute exacerbations of schizophrenia [ J ]. J Clin Psychopharmacol, 2008, 28 (2 Suppl 1 ) :S20-28.
  • 2Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER) : results of a 6-week, randomized, placebo-controlled study [ J ]. Schizophr Res, 2007, 93 ( 1 ) : 117- 130.
  • 3Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial [ J ]. Schizophr Res, 2007,90 ( 1 ) : 147-161.
  • 4Keck PE, Orsulak PJ, Cutler A J, etal. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study [J]. J Affect Disord, 2009, 112( 1 ) :36-49.
  • 5Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6- week, randomized, double-blind, placebo-controlled trial [J]. J Am Acad Child Adolesc Psychiatry, 2009, 48 ( 1 ) : 60 -70.
  • 6Keitner GI, Garlow S J, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression[J]. J Psychiatr Res,2009 , 43(3) :205-214.
  • 7Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebocontrolled study with six-month olden-label extension[ J]. Am J Geriatr Psychiatry,2008,16( 1 ) :31-43.
  • 8McEvoy JP, Daniel DG, Carson WH Jr, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10,15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia [ J ]. J Psychiatr Res, 2007,41 ( 11 ) : 895-905.
  • 9Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania[ J ]. Am J Psychiatry,2007 , 164 (10) : 1547-1556.
  • 10Vieta E, Calabrese JR, Goikolea JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study [ J ]. Bipolar Disord,2007 ,9( 4 ) :413-425.

共引文献6

同被引文献10

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部